-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Fetuin-A (fetuin) has the ability to prevent vascular calcification, in addition, it is associated with metabolic dysfunction, insulin resistance and the risk of diabetes , but whether fetuin-A is related to the risk of vascular complications in diabetic patients is currently unknown.
Fetuin-A (fetuin) has the ability to prevent vascular calcification, in addition, it is associated with metabolic dysfunction, insulin resistance and the risk of diabetes , but whether fetuin-A is related to the risk of vascular complications in diabetic patients is currently unknown.
587 participants with type 2 diabetes and no microvascular and macrovascular disease were investigated with a median follow-up of 13 years
In the multivariate model, fetuin-A was linearly inversely associated with the occurrence of gross and microvascular complications, and fetuin-A was linearly inversely associated with the occurrence of gross and microvascular complications, per standard deviation (SD) Increased hazard ratio (HR, 95% CI): total 0.
Association of fetuin A concentrations with risk of diabetes-related vascular complications
Association of fetuin A concentrations with risk of diabetes-related vascular complications
In short, in T2D patients, lower prediagnostic fetuin-A levels were associated with a higher risk of vascular complications, especially microvascular complications, independent of established cardiometabolic risk factors
Reference: Birukov, A.
, Polemiti, E.
, Jäger, S.
et al.
Fetuin-A and risk of diabetes-related vascular complications: a prospective study.
Cardiovasc Diabetol 21, 6 (2022).
https://doi .
org/10.
1186/s12933-021-01439-8 https://doi.
org/10.
1186/s12933-021-01439-8
Comment here
